BFLY:NYE-Butterfly Network, Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 10.99

Change

-0.32 (-2.83)%

Market Cap

USD 2.08B

Volume

1.05M

Avg Analyst Target

USD 20.00 (+81.98%)

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Butterfly Network, Inc., a digital health company, develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. It offers Butterfly iQ, a handheld and single-probe whole body ultrasound system; and Butterfly iQ+, a point-of-care ultrasound imaging device that connects with a smart phone or tablet. The company serves healthcare practitioners. Butterfly Network, Inc. was incorporated in 2011 and is headquartered in Guilford, Connecticut.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

-0.73 (-0.61%)

USD211.41B 37.29 21.35
MDT Medtronic plc

+0.06 (+0.05%)

USD170.74B 47.76 24.00
SYK Stryker Corporation

+0.42 (+0.16%)

USD97.46B 70.10 36.35
EW Edwards Lifesciences Corporati..

+1.01 (+0.95%)

USD65.92B 78.61 61.83
BSX Boston Scientific Corporation

-0.03 (-0.07%)

USD61.92B 309.08 39.72
ZBH Zimmer Biomet Holdings, Inc

-0.91 (-0.57%)

USD33.27B 58.54 22.84
BIO-B Bio-Rad Laboratories, Inc

N/A

USD20.06B 4.97 3.53
BIO Bio-Rad Laboratories, Inc

+12.36 (+1.86%)

USD19.74B 4.88 3.50
SNN Smith & Nephew plc

+0.07 (+0.16%)

USD18.80B 41.63 22.35
PEN Penumbra, Inc

+2.48 (+0.94%)

USD9.66B 937.69 490.23

ETFs Containing BFLY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.08B 40% F 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.47 32% F 18% F
Price / Cash Flow Ratio -1,633.95 100% A+ 99% A+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -220.43% 4% F 6% F
Return on Invested Capital 104.96% 100% A+ 99% A+
Return on Assets -64.68% 8% F 0% N/A
Debt to Equity Ratio -14.89% 100% A+ 95% A
Technical Ratios  
Short Ratio 4.42 32% F 18% F
Short Percent 12.62% 13% F 25% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.